Evidence map›Paper›PMID 37178920›Full record

ArticleThe Journal of biological chemistry2023

A selective nonpeptide somatostatin receptor 5 agonist effectively decreases insulin secretion in hyperinsulinism.

Christine A Juliana, Jinghua Chai, Pablo Arroyo, Elizabeth Rico-Bautista, Stephen F Betz, Diva D De León

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of biological chemistry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Redox Regulation of KAntioxidants & redox signaling · 2024
    Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Christine A JulianaDivision of Endocrinology and Diabetes, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
Jinghua ChaiDivision of Endocrinology and Diabetes, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
Pablo ArroyoCrinetics Pharmaceuticals, Inc, San Diego, California, USA.
Elizabeth Rico-BautistaCrinetics Pharmaceuticals, Inc, San Diego, California, USA.
Stephen F BetzCrinetics Pharmaceuticals, Inc, San Diego, California, USA.
Diva D De LeónDivision of Endocrinology and Diabetes, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA; Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA. Electronic address: deleon@chop.edu.
Children's Hospital of Philadelphia · USCrinetics Pharmaceuticals (United States) · US

Funding

VIRAL VECTOR COREP30DK019525 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI Patrick Seale · 1986 to 2026
$48.3M
NIDDK NIH HHS P30 DK019525
6 · The paper itself

Abstract

Congenital hyperinsulinism (HI), a beta cell disorder most commonly caused by inactivating mutations of beta cell K

Indexed as

HyperinsulinismReceptors, SomatomedinAdenosine TriphosphateAmino AcidsAnimalsChildGlucoseHumansHypoglycemiaInfantInsulinInsulin SecretionIslets of LangerhansMiceMutationPotassium Channels, Inwardly RectifyingAdenosine TriphosphateAmino AcidsGlucoseInsulinPotassium Channels, Inwardly RectifyingReceptors, SomatomedinReceptors, Somatostatinsomatostatin receptor 5beta cellscongenital hyperinsulinismhypoglycemiainsulin secretionsomatostatin receptor

Identifiers

PMID37178920
PMCPMC10318504
OpenAlexW4376127766

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.